Table 4. Pathway involved in the CHD-PAH patients compared to CHD.
| # | Pathway | Diff Proteins with pathway annotation* | All Proteins with pathway annotation (1009) | P value | Pathway ID |
|---|---|---|---|---|---|
| VSD-PAH/VSD | |||||
| 1 | PPAR signaling pathway | 4/39 (10.26%) | 10 (0.99%) | 0.000339653 | ko03320 |
| 2 | Focal adhesion | 3/39 (7.69%) | 14 (1.39%) | 0.01447198 | ko04510 |
| 3 | ECM-receptor interaction | 3/39 (7.69%) | 11 (1.09%) | 0.007112038 | ko04512 |
| 4 | Chemokine signaling pathway | 2/39 (5.13%) | 4 (0.4%) | 0.008320181 | ko04062 |
| 5 | Cytokine-cytokine receptor interaction | 2/39 (5.13%) | 5 (0.5%) | 0.01352894 | ko04060 |
| 6 | Vitamin digestion and absorption | 2/39 (5.13%) | 7 (0.69%) | 0.02704753 | ko04977 |
| 7 | Type II diabetes mellitus | 1/39 (2.56%) | 1 (0.1%) | 0.03865213 | ko04930 |
| 8 | Adipocytokine signaling pathway | 1/39 (2.56%) | 1 (0.1%) | 0.03865213 | ko04920 |
| ASD-PAH/ASD | |||||
| 1 | Complement and coagulation cascades | 4/19 (21.05%) | 64 (6.34%) | 0.02773601 | ko04610 |
| 2 | Focal adhesion | 2/19 (10.53%) | 14 (1.39%) | 0.0267276 | ko04510 |
| 3 | Alcoholism | 1/19 (5.26%) | 2 (0.2%) | 0.03732479 | ko05034 |
| 4 | Neuroactive ligand-receptor interaction | 1/19 (5.26%) | 3 (0.3%) | 0.05548847 | ko0408 |
| Mix-PAH/Mix | |||||
| 1 | Malaria | 4/49 (8.16%) | 7 (0.69%) | 0.000154843 | ko05144 |
| 2 | Aminoacyl-tRNA biosynthesis | 2/49 (4.08%) | 2 (0.2%) | 0.002312521 | ko00970 |
| 3 | Osteoclast differentiation | 2/49 (4.08%) | 3 (0.3%) | 0.006721696 | ko04380 |
| 4 | Cytokine-cytokine receptor interaction | 2/49 (4.08%) | 5 (0.5%) | 0.02103969 | ko04060 |
| 5 | Vitamin digestion and absorption | 2/49 (4.08%) | 7 (0.69%) | 0.04150761 | ko04977 |
| 6 | TGF-beta signaling pathway | 2/49 (4.08%) | 7 (0.69%) | 0.04150761 | ko04350 |
| 7 | Endocytosis | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko04144 |
| 8 | Renal cell carcinoma | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko05211 |
| 9 | Mineral absorption | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko04978 |
| 10 | Colorectal cancer | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko05210 |
| 11 | Glycosaminoglycan degradation | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko00531 |
| 12 | HTLV-I infection | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko05166 |
| 13 | Toxoplasmosis | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko05145 |
| 14 | Valine, leucine and isoleucine degradation | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko00280 |
| 15 | Cell cycle | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko04110 |
| 16 | Chronic myeloid leukemia | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko05220 |
| 17 | Pancreatic cancer | 1/49 (2.04%) | 1 (0.1%) | 0.04856293 | ko05212 |
*The numerator is the number of proteins identified from the proteomic study associated to this pathway and the denominator is the total number of proteins known to be associated to this pathway.